http://www.angirx.com/blog/hypertensive-heart-disease-emedicine/
hypertensive heart disease emedicine
[mage lang="" source="flickr"]hypertensive heart disease emedicine[/mage]
What doctors say about primary pulmonary hypertension and Fen-Phen
While some organizations and practitioners caring for their efforts to be vague or even tangentially, on the relationship between PPH (primary pulmonary hypertension) and fen-phen, others show openly what is known about this association.
Ronald J. Oudiz, MD, Director of Pulmonary Hypertension, Associate Professor, Department Medicine, Division of Cardiology, Harbor-UCLA Medical Center indicated (eMedicine) that:
PPH (primary pulmonary hypertension), more recently, called IpaH (idiopathic pulmonary arterial hypertension) anorectics has been associated with other alpha-adrenergic (fen-phen). How these PPH associated conditions predispose to or cause remains unknown.
In the United States, IpaH (PPH) is responsible for approximately 125-150 deaths per year.
In general, young women of childbearing age develop IpaH (PPH). However, it can affect women in their fifth and sixth years of life or more.
The mortality rate for untreated IpaH (PPH) is about 50% at 3 years (depending on the seriousness of the screen).
The American Heart Association indicates that approximately 500 to 1,000 new estimated cases of PPH are diagnosed each year in the United States. The largest number reported in women between the ages of 20 and 40. However, men and women of all ages and very young children to develop PPH.
Anorectics (fen-phen) are among the factors thought to trigger constriction or narrowing of the pulmonary artery.
A website dedicated to information on primary pulmonary hypertension or PPH States Pulmonary Hypertension may be linked to drug supply fen-phen:
A significant association between use of fen-phen diet drug and PPH. Studies have shown that it may be several years (ten or more) after having stopped taking diet drugs that patients develop the disease.
According to the American Lung Association reports that in 2000 there were 3065 deaths attributed to PPH. The organization also states that: The use of inhibitors appetite of some (fen-phen) was found to increase the risk of developing PPH, especially use lasting more than three months.
They note that studies estimate that treatment with certain appetite suppressant drugs (fen-phen) increases the risk of PPH How about 1 to 28 cases per million person-years (person-year represents a patient for one year). Two drugs associated with PPH, fenfluramine (a component of fen-phen) and dexfenfluramine were withdrawn from the market in September 1997 after being linked to heart valve disorders.
The National Heart Lung and Blood Institute identifies factors that appear to increase the likelihood of developing pulmonary hypertension (PAH. They include the use of appetite suppressants, particularly fenfluramine (fen-phen) and dexfenfluramine.
About the Author
Nick Johnson is lead counsel with Johnson Law Group. Johnson represents plaintiffs in many states and focuses on injury cases involving Fen-Phen and PPH, Paxil, Mesothelioma and Nursing Home Abuse. Call 1-888-311-5522 today or visit http://www.jbclawfirm.com
[mage lang="en|es|fr|en" source="answers"]hypertensive heart disease emedicine[/mage]
[affmage source="amazon" results="3"]hypertensive heart disease emedicine[/affmage]
[affmage source="clickbank" results="2"]hypertensive heart disease emedicine[/affmage]
[affmage source="cj" results="1"]hypertensive heart disease emedicine[/affmage]